Latest Earnings Results: Q2 '26
Estimated EPS
-$0.15
Reported EPS
-$0.18
Surprise
-20%
Estimated Rev
$0M
Reported Rev
---
Surprise
---
PDS Biotechnology Corporation reported a net loss of $9.8 million, or $0.18 per basic and diluted share, for the three months ended June 30, 2026, compared to $9.4 million in 2025.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.11 | -- | -- | N/A |
Q2 '26 | -$0.15 | -$0.18 | -20.00% | MISSED |
Q1 '26 | -$0.14 | -$0.13 | 7.14% | BEAT |
Q4 '25 | -$0.20 | -$0.13 | 35.00% | BEAT |
Q3 '25 | -$0.20 | -$0.19 | 3.39% | BEAT |